GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning

benzinga.com/news/fda/25/07/46489262/gsks-blood-cancer-drug-faces-us-setback-due-to-fda-panels-eye-safety-warning

The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of GSK plc’s (NYSE:GSK) Blenrep (belantamab mafodotin-blmf) combinations.
The belantamab mafodotin combinations were evaluated in…

This story appeared on benzinga.com, 2025-07-18 11:32:19.
The Entire Business World on a Single Page. Free to Use →